We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

94 hedge funds and large institutions have $122M invested in Five Prime Therapeutics, Inc. in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $105M → $122M (+$17.5M)

8% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 37

9% less funds holding

Funds holding: 10394 (-9)

50% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 18

75% less call options, than puts

Call options by funds: $4K | Put options by funds: $16K

Holders
94
Holders Change
-9
Holders Change %
-8.74%
% of All Funds
1.85%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
34
Reduced
37
Closed
18
Calls
$4K
Puts
$16K
Net Calls
-$12K
Net Calls Change
+$488K

FPRX Hedge Fund Activity: Q4 2019 in Review

94 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2019, worth a combined $122M — up 17% from $105M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of FPRX and 9 opened new positions — a net loss of 9 holders — while 37 trimmed existing stakes and 34 added.

The largest buyer was BVF Inc, adding an estimated $15.9M. The largest seller was Wellington Management Group, cutting an estimated $4.62M.

  • 94 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2019, down from 103 in Q3 2019.
  • Funds reported $122M of Five Prime Therapeutics, Inc. stock for Q4 2019, up 17% quarter-over-quarter.
  • 9 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2019 and 18 closed out, a net change of -9 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q4 2019 was BVF Inc, an estimated $15.9M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q4 2019 was Wellington Management Group, an estimated $4.62M sold.

Based on aggregated 13F filings for Q4 2019.